Johnson & Johnson (JNJ)
Pharmaceutical Preparations · New Brunswick, NJ
Our rating: Neutral
Neutral reaffirmed at $267.61, moderate conviction, October 22, 2026.
Breaks if: The Neutral call turns Cautious if reported revenue growth slows below 3% for two consecutive quarters, or if annual free cash flow falls below $16B — either condition would indicate litigation outflows or volume erosion are biting harder than the current figures imply. It turns Positive if free cash flow closes to within 10% of net income for two straight quarters while top-line growth holds above 7% — the clearest combination signaling that the cash drag is easing and the franchise is compounding cleanly.
Key figures
| Market value | $651.1B |
|---|---|
| Revenue, last 12 months | $99.3B |
| Net income, last 12 months | $16.1B |
| Free cash flow, last 12 months | $20.6B |
| Price to earnings | 40.5× |
| Free cash flow yield | 3.2% |
| Dividend yield | 2.0% |
| Operating margin | n/a |
| Return on equity | 20.0% |
| Beta to the S&P 500 | −0.01 |
| Volatility, annualized | 19.5% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 27, 2026 | $25.4B | 5.9% | $0.09 | $6.4B |
| June 28, 2026 | $25.3B | 6.6% | $2.27 | $7.3B |
| March 29, 2026 | $24.1B | 9.9% | $2.14 | $1.5B |
| December 28, 2025 | $24.6B | 9.1% | $2.09 | $5.5B |
| September 28, 2025 | $24.0B | 6.8% | $2.12 | $8.0B |
| June 29, 2025 | $23.7B | 5.8% | $2.29 | $2.8B |
| March 30, 2025 | $21.9B | 2.4% | $4.54 | $3.4B |
| December 29, 2024 | $22.5B | 5.3% | $1.41 | $5.4B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $26.5B: Claude 62%, Gemini 60%, Mistral 58%
- Diluted earnings per share are at least $2.09: Claude 45%, Gemini 90%, Mistral 65%
- Free cash flow for the quarter is at least $5.47B: Claude 52%, Gemini 35%, Mistral 70%
17 ledger entries and 27 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.